Mitrajit Ghosh

Dr. Mitrajit Ghosh

Instytut Biologii Doświadczalnej im. Marcelego Nenckiego, Warsaw, Mazowieckie, Poland
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in Cancer Cell
Verified
Journal Article
Closed access
AGAmelie Griveau
Amelie Griveau
Giorgio SeanoGiorgio Seano
Giorgio Seano
SSSamuel J. Shelton
Samuel J. Shelton
RKRobert Kupp
Robert Kupp
AJArman Jahangiri
Arman Jahangiri
DRDavid H. Rowitch
David H. Rowitch

7 January 2019 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
Giorgio SeanoGiorgio Seano
Giorgio Seano
HNHadi T. Nia
Hadi T. Nia
KEKyrre Emblem
Kyrre Emblem
MDMeenal Datta
Meenal Datta
JRJun Ren
Jun Ren
RJRakesh K. Jain
Rakesh K. Jain

11 May 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
ZAZohreh Amoozgar
Zohreh Amoozgar
JKJonas Kloepper
Jonas Kloepper
JRJun Ren
Jun Ren
RTRong En Tay
Rong En Tay
SKSamuel W. Kazer
Samuel W. Kazer
RJRakesh K. Jain
Rakesh K. Jain
Immune checkpoint blockers (ICBs) have failed in all phase III glioblastoma (GBM) trials. Here, we show that regulatory T (Treg) cells play a key role in GBM resistance to ICBs in experimental gliomas. Targeting glucocorticoid-induced TNFR-related receptor (GITR) in Treg cells using an agonistic antibody (αGITR) promotes CD4 Treg cell differentiation into CD4 effector T cells, alleviates Treg cell-mediated suppression of anti-tumor immune response, and induces potent anti-tumor effector cells in GBM. The reprogrammed GBM-infiltrating Treg cells express genes associated with a Th1 response signature, produce IFNγ, and acquire cytotoxic activity against GBM tumor cells while losing their suppressive function. αGITR and αPD1 antibodies increase survival benefit in three experimental GBM models, with a fraction of cohorts exhibiting complete tumor eradication and immune memory upon tumor re-challenge. Moreover, αGITR and αPD1 synergize with the standard of care treatment for newly-diagnosed GBM, enhancing the cure rates in these GBM models.

7 October 2015 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
Mitrajit GhoshMitrajit Ghosh
Mitrajit Ghosh
MBMatilde Balbi
Matilde Balbi
FHFarida Hellal
Farida Hellal
MDMartin Dichgans
Martin Dichgans
ULUte Lindauer
Ute Lindauer
NPNikolaus Plesnila
Nikolaus Plesnila

20 October 2011 in Small
Verified
Journal Article
Closed access
PDF file
Mitrajit GhoshMitrajit Ghosh
Mitrajit Ghosh
SSSumit Kumar Sonkar
Sumit Kumar Sonkar
MSManav Saxena
Manav Saxena
Sabyasachi SarkarSabyasachi Sarkar
Sabyasachi Sarkar

10 June 2015 in Journal of Cerebral Blood Flow & Metabolism
Verified
Journal Article
Open access
MBMatilde Balbi
Matilde Balbi
Mitrajit GhoshMitrajit Ghosh
Mitrajit Ghosh
TLThomas A Longden
Thomas A Longden
MVMax Jativa Vega
Max Jativa Vega
BGBenno Gesierich
Benno Gesierich
NPNikolaus Plesnila
Nikolaus Plesnila
Aging leads to a gradual decline in the fidelity of cerebral blood flow (CBF) responses to neuronal activation, resulting in an increased risk for stroke and dementia. However, it is currently unknown when age-related cerebrovascular dysfunction starts or which vascular components and functions are first affected. The aim of this study was to examine the function of microcirculation throughout aging in mice. Microcirculation was challenged by inhalation of 5% and 10% CO2 or by forepaw stimulation in 6-week, 8-month, and 12-month-old FVB/N mice. The resulting dilation of pial vessels and increase in CBF was measured by intravital fluorescence microscopy and laser Doppler fluxmetry, respectively. Neurovascular coupling and astrocytic endfoot Ca2+ were measured in acute brain slices from 18-month-old mice. We did not reveal any changes in CBF after CO2 reactivity up to an age of 12 months. However, direct visualization of pial vessels by in vivo microscopy showed a significant, age-dependent loss of CO2 reactivity starting at 8 months of age. At the same age neurovascular coupling was also significantly affected. These results suggest that aging does not affect cerebral vessel function simultaneously, but starts in pial microvessels months before global changes in CBF are detectable.